Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H15N3O2.ClH |
Molecular Weight | 269.727 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CN1CCN(CC1)C2=C3OC(=O)NC3=CC=C2
InChI
InChIKey=NQRIKTDKFHAOKC-UHFFFAOYSA-N
InChI=1S/C12H15N3O2.ClH/c1-14-5-7-15(8-6-14)10-4-2-3-9-11(10)17-12(16)13-9;/h2-4H,5-8H2,1H3,(H,13,16);1H
Molecular Formula | C12H15N3O2 |
Molecular Weight | 233.2664 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Pardoprunox is a partial D2/3 dopamine receptor agonist and full 5-HT1A serotonin receptor agonist. Partial D(2/3) dopamine (DA) receptor agonists provide a novel approach to the treatment of the motor symptoms of Parkinson's disease that may avoid common dopaminergic side effects, including dyskinesia and psychosis. Pardoprunox passed phase III clinical trial for the treatment of Parkinson's disease.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL214 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20434890 |
8.5 null [pKi] | ||
Target ID: CHEMBL217 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20434890 |
8.1 null [pKi] | ||
Target ID: CHEMBL234 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20434890 |
8.6 null [pKi] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | PARDOPRUNOX Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
New frontiers in the pharmacological management of Parkinson's disease. | 2008 Jul |
|
Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease. | 2009 |
|
The Movement Disorder Society--14th International Congress of Parkinson's Disease and Movement Disorders. | 2010 Aug |
|
An in vivo pharmacological evaluation of pardoprunox (SLV308)--a novel combined dopamine D(2)/D(3) receptor partial agonist and 5-HT(1A) receptor agonist with efficacy in experimental models of Parkinson's disease. | 2010 Aug |
|
The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets. | 2010 Dec |
|
Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets. | 2010 Oct 15 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/20198713
Pardoprunox was titrated to each patient’s optimal dose (9–45 mg/d) over 2 to 6 weeks and then maintained at this dose for a further 3 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/17001660
At cloned human dopamine D2 receptors, pardoprunox (SLV308) acted as a potent but partial agonist (pEC50 = 8.0) with an efficacy of 50% on forskolin-stimulated cAMP accumulation. At human recombinant dopamine D3 receptors, SLV308 acted as a partial agonist in the induction of [(35)S]GTPgammaS binding (an intrinsic activity of 67%; pEC50 = 9.2). SLV308 acted as a full 5-HT1A receptor agonist on forskolin-induced cAMP accumulation at cloned human 5-HT1A receptors but with low potency (pEC50 = 6.3).
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:36:59 GMT 2023
by
admin
on
Fri Dec 15 16:36:59 GMT 2023
|
Record UNII |
U40903X6V8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C81081
Created by
admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
|
PRIMARY | |||
|
CHEMBL2103832
Created by
admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
|
PRIMARY | |||
|
DBSALT002129
Created by
admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
|
PRIMARY | |||
|
U40903X6V8
Created by
admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
|
PRIMARY | |||
|
6918524
Created by
admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
|
PRIMARY | |||
|
300000044494
Created by
admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
|
PRIMARY | |||
|
269718-83-4
Created by
admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
|
PRIMARY | |||
|
UU-84
Created by
admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
|
PRIMARY | |||
|
DTXSID80949746
Created by
admin on Fri Dec 15 16:36:59 GMT 2023 , Edited by admin on Fri Dec 15 16:36:59 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |